3 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
demonstrated single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of ALG-097558 were well tolerated in healthy volunteers
Aligos Therapeutics Presents Clinical Data At ESCMID 2024 From The ALG-097558 Phase 1 Study
ALGS
25 Apr 24
were well tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect."We are pleased
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
tolerated in healthy volunteers with a PK profile supporting twice daily ritonavir-free dosing without a food effect. "We are pleased to present
- Prev
- 1
- Next